Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer - PubMed (original) (raw)

Comparative Study

Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer

S Ganesh et al. Br J Cancer. 1997.

Free PMC article

Abstract

Despite the advances in pre-, peri- and post-operative medical care of colorectal carcinoma patients, the prognosis has improved only marginally over recent decades. Thus, additional prognostic indicators would be of great clinical value to select patients for adjuvant therapy. In previous studies we found that colorectal carcinomas have a marked increase of the urokinase-type of plasminogen activator (u-PA), and the inhibitors PAI-1 and PAI-2, whereas the tissue-type plasminogen activator (t-PA) is found to be decreased in comparison with adjacent normal mucosa. In the present study we evaluated the prognostic value of several plasminogen activation parameters, determined in both normal and carcinomatous tissue from colorectal resection specimens, for overall survival of 136 Dukes' stage B and C colorectal cancer patients, in relation to major clinicopathological parameters. Uni- and multivariate analyses indicated that a high PAI-2 antigen level in carcinoma, a low t-PA activity and antigen level and a high u-PA/t-PA antigen ratio in adjacent normal mucosa are significantly associated with a poor overall survival. A high ratio of u-PA antigen in the carcinomas and t-PA antigen in normal mucosa, i.e. u-PA(C)/t-PA(N), was found to be predictive of a poor overall survival as well. All these parameters were found to be prognostically independent of the clinicopathological parameters. Multivariate analysis of combinations of these prognostically significant plasminogen activation parameters revealed that they are important independent prognostic indicators and have in fact a better prognostic value than their separate components. Based on these combined parameters, subgroups of patients with Dukes' stage B and C colorectal cancer could be identified as having either a high or a low risk regarding overall survival. In conclusion, these findings emphasize the relevance of the intestinal plasminogen activation system for survival prognosis of patients with colorectal cancer and, in the future, might constitute a patient selection criterion for adjuvant therapy.

PubMed Disclaimer

Similar articles

• Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
  Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB, et al. Ganesh S, et al. Cancer Res. 1994 Aug 1;54(15):4065-71. Cancer Res. 1994. PMID: 8033138
• Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
  Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers CB, Verspaget HW. Ganesh S, et al. Cancer. 1996 Mar 15;77(6):1035-43. doi: 10.1002/(sici)1097-0142(19960315)77:6<1035::aid-cncr5>3.0.co;2-g. Cancer. 1996. PMID: 8635120
• Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
  Sier CF, Verspaget HW, Griffioen G, Verheijen JH, Quax PH, Dooijewaard G, De Bruin PA, Lamers CB. Sier CF, et al. Gastroenterology. 1991 Dec;101(6):1522-8. doi: 10.1016/0016-5085(91)90387-z. Gastroenterology. 1991. PMID: 1955118
• Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
  Verspaget HW, Sier CF, Ganesh S, Griffioen G, Lamers CB. Verspaget HW, et al. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1105-9. doi: 10.1016/0959-8049(95)00170-n. Eur J Cancer. 1995. PMID: 7577001 Review.
• Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
  Gandolfo GM, Conti L, Vercillo M. Gandolfo GM, et al. Anticancer Res. 1996 Jul-Aug;16(4B):2155-9. Anticancer Res. 1996. PMID: 8694536 Review.

Cited by

• Regulation of the human plasminogen activator inhibitor type 2 gene: cooperation of an upstream silencer and transactivator.
  Stringer B, Udofa EA, Antalis TM. Stringer B, et al. J Biol Chem. 2012 Mar 23;287(13):10579-10589. doi: 10.1074/jbc.M111.318758. Epub 2012 Feb 9. J Biol Chem. 2012. PMID: 22334683 Free PMC article.
• Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
  Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE, Ellis LM. Bauer TW, et al. Ann Surg. 2005 May;241(5):748-56; discussion 756-8. doi: 10.1097/01.sla.0000160699.59061.92. Ann Surg. 2005. PMID: 15849510 Free PMC article.
• Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.
  Scicolone G, Sanchez V, Vauthay L, Fuentes F, Scicolone A, Scicolone L, Rapacioli M, Flores V. Scicolone G, et al. J Cancer Res Clin Oncol. 2006 May;132(5):309-19. doi: 10.1007/s00432-005-0066-4. Epub 2005 Dec 21. J Cancer Res Clin Oncol. 2006. PMID: 16369808
• Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
  Herszényi L, Farinati F, Cardin R, István G, Molnár LD, Hritz I, De Paoli M, Plebani M, Tulassay Z. Herszényi L, et al. BMC Cancer. 2008 Jul 10;8:194. doi: 10.1186/1471-2407-8-194. BMC Cancer. 2008. PMID: 18616803 Free PMC article.
• ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer.
  Mazzoccoli G, Pazienza V, Panza A, Valvano MR, Benegiamo G, Vinciguerra M, Andriulli A, Piepoli A. Mazzoccoli G, et al. J Cancer Res Clin Oncol. 2012 Mar;138(3):501-11. doi: 10.1007/s00432-011-1126-6. Epub 2011 Dec 24. J Cancer Res Clin Oncol. 2012. PMID: 22198637

References

1. 1. Surg Gynecol Obstet. 1978 Feb;146(2):257-9 - PubMed
2. 1. Cancer Res. 1992 Nov 1;52(21):6101-5 - PubMed
3. 1. Rehabil Nurs. 1981 Jan-Feb;6(1):11-5 - PubMed
4. 1. Cancer. 1981 Mar 1;47(5):930-6 - PubMed
5. 1. Thromb Haemost. 1982 Dec 27;48(3):266-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal